Allergan PLC's antipsychotic Vraylar became the 25th novel drug approved by FDA's Center for Drug Evaluation and Research in 2015. New submissions were plentiful, including a first-line claim for AbbVie Inc. and Johnson & Johnson's Imbruvica, and another breakthrough designation was awarded to Bristol-Myers Squibb Co.'s checkpoint inhibitor immunotherapy Opdivo.
The atypical antipsychotic Vraylar (cariprazine) was approved on Sept. 17 to treat schizophrenia and acute manic or mixed episodes of...